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introduction
Glycosaminoglycans (GAGs) are composed of long sugar chains containing 
repeating units of highly sulfated, alternating hexuronic acid, and hexosamine 
residues. Keratan sulfate (KS), heparan sulfate (HS), dermatan sulfate (DS), and 
chondroitin sulfate (CS) are the main types of GAGs (1-4). GAGs are important 
components of plasma membranes and the extra-cellular matrix (5,6).
GAG metabolic abnormality is due to enzyme deficiency results in the progressive
accumulation of the molecules and leads to an imperceptible deterioration of
Abstract 
Objective
The first line-screening test for mucopolysaccharidosis is based on measurement
of urinary glycosaminoglycans. The most reliable test for measurement of urine
glycosaminoglycans is the 1,9-dimethyleneblue colorimetric assay. Biological
markers  are  affected  by  ethnical  factors,  for  this  reason,  the  World  Health
Organization recommends that the diagnostic test characteristics should be used to
determine results for different populations. This study determines the diagnostic
value of 1,9-dimethyleneblue tests for diagnosis of mucopolysaccharidosis type
I patients in Iran.
Materials & Methods
In addition to routine urine analysis, the qualitative and quantitative measurements 
of urine glucosaminoglycans were performed with the Berry spot test and 
1,9-dimethyleneblue assay. Diagnostic values of the tests were determined using 
the ROC curve.
Results
Urine total glycosaminoglycans were significantly higher in male subjects than 
in female subjects. Glycosaminoglycan concentration was markedly decreased 
in specimens with elevated white blood cell and epithelial cells count. Using a 
cut-off level of 10.37  mg/g creatinine,  sensitivity, and specificity  were 100% 
and 97.22%, respectively, for a 1,9-dimethyleneblue colorimetric assay.
Conclusion
Urine  glycosaminoglycans  concentration  significantly  differs  in  our  studied
population. In addition to determine diagnostic validity of the 1,9-dimethyleneblue
test, our results demonstrate the usefulness of measuring glycosaminoglycans 
for early screening of mucopolysaccharidosis type I Iran.
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cells, tissues, and organs that may lead to the onset of
a mucopolysaccharidosis (MPS) clinical phenotype 
(7,8). There are 11 enzyme deficiencies that result 
in seven distinct MPS clinical syndromes and their
subtypes. Mucopolysaccharidosis type I (MPSI, Mc
Kusick 252800) is an inherited autosomal recessive
disease that results from a deficiency of α-L-iduronidase
(IDUA; EC3.2.1.76) activity and results in progressive
accumulation of dermatan and heparan sulfate, in
lysosomes that may cause the clinical phenotype within
a spectrum of severity ranging from severe Hurler
syndrome to relatively mild Scheie syndrome (8-12).
Definitive diagnosis of a specific type of the MPS
syndrome is based on enzyme analysis (13). It is not
reasonable to check all 11 enzymes for every suspected
patient. A simple screening test, along with clinical
features, is needed to limit the list of potential patients
and enzymes to be assayed (14). It is known that all MPS
lead to increased urinary GAGs excretion. Therefore,
a first line-screening assay for MPSs is a complete
quantitative and qualitative analysis of urinary GAGs
in suspected patients to avoid tedious and expensive
further laboratory testing of patients (7,15). Numerous
methods have been developed for this purpose. The
Berry spot test provides a rapid qualitative evaluation
of urine. GAGs react with toluidine blue, a cationic dye,
to yield a purple colored compound (8, 16-18). Today,
a spectrophotometric assay using 1,9-dimethyleneblue
(DMB) has been developed and is regarded as being
more reliable than earlier quantitative methods
such as the uronic acid carbazole test (8). Little data
exists on diagnostic value of urinary GAGs levels for
different ethnic groups and there are no other studies
that investigate the role of this marker in the Iranian
population. Therefore, in this paper, we study the
diagnostic efficiency of urinary GAGs in Iranian MPSI
patients to the primary screening of MPSI.
Materials & Methods
Subjects
In this study, all patients were identified as likely cases
for MPS from clinical phenotypes between January
2011 and October 2013 were examined for MPS. From
this, we identified 15 subjects who were diagnosed
as MPSI patients. Diagnosis of MPSI was male by 
fluorometric measurement of alpha-L-Iduronidase
activity in dried blood spot samples. A total of 185
cases (ages: 1-month to 18 years of age) who were
admitted to Besat Hospital in Sanandaj (Kurdistan,
Iran) were enrolled in the study as the control group.
Written informed consent was obtained and the project
was approved by the Research Ethics Committee of
Tarbiat Modares University (Tehran, Iran). Patients
who were being treated with Laronidase were excluded
from this study. All subjects were categorized into 6
groups according to age and named as group 1 (less
than 1 years old), group 2 (1–2 years old), group 3 (2–5
years old), group 4 (5–9 years old), and group 5 (9–18
years old). Three patients were in the age group 2–5
years and 12 patients were in the age group 4.
Urine collection
Random urine specimens were used for the Berry spot test
and the DMB assay. Samples from early morning are not
good specimens, because of higher excretion of GAGs
than creatinine. During the day, the GAG:creatinine
ratio remains constant (19). The urine samples were
collected in sterile bottles without any preservatives
and the physical, chemical, and microscopic properties
of the urine were recorded by general urine analysis
examination then stored at -80°C pending analysis.
Urine sediment analysis
A sample of 10–15 ml well-mixed urine was
centrifuged in a test tube at 2500 rpm for 5–10 minutes.
The supernatant was decanted and the sediment was
resuspended in the remaining supernatant by flicking
the bottom of the tube several times. A drop of
resuspended sediment was poured onto a glass slide
and coverslipped. The sediment was first examined for
crystals, casts, squamous cells, and other large objects
under low power to identify most. Several fields were
averaged and the number of these elements reported
as the number for each type found per low power
field (LPF). Next, the examination was carried out at
a high power to identify crystals, cells, and bacteria.
The various types of cells were usually described as
the number of each type found per average high power
field (HPF) (20, 21). GAGs
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Spot test
Urine samples were first evaluated for urinary excretion
of mucopolysaccharides by Berry spot test using a
toluidine blue dye and positive results double-checked.
Briefly, 50 μl urine sample is spotted onto filter paper
strips (Whatman 903 paper, Whatman, Dassel Germany);
the paper is then dipped in toluidine blue dye solution
(Merck, Germany) for 2 min. Subsequently, the paper
is dried and the excessive dye is removed by washing
with 1.8 M acetic acid and demineralized water. Positive
samples will become purple against a bluish background
(16, 22).
Quantitative measurement of urinary gAgs
Urine creatinine was measured with commercial
enzymatic kits (Pars Azmoon, Tehran, Iran), according
to the manufacturer’s instructions. 1,9-dimethylene blue
was purchased from Sigma-Aldrich (Sigma, Missouri,
USA). Urinary GAGs was measured calorimetrically
according to the previously described method (23).
Concisely, based on reaction of DMB with urinary
mucopolysaccharides, the complex was quantified
spectrophotometrically in 520nm after 3 min. Results
were expressed in mg/g creatinine.
Statistical analysis
Data   was    analyzed    with    SPSS 16    (SPSS    Inc., 
Chicago). Results were presented as Mean±SD and
independent samples T-test were used to compare mean
differences.  Moreover, a  one-way  ANOVA  followed
by a Post Hoc and Tukey and Dunnett tests were used
to analyze differences between groups and a p value
less than 0.05 was considered significant. Receiver
operating characteristic (ROC) curves were constructed
to establish a sensitivity-specificity relationship. Cut-off
values that provided the best combination of sensitivity
and specificity were determined by ROC curve analysis.
The coefficient of variances of the test, sensitivity
(true-positive/true-positive+false-negative), specificity
(true-negative/true-negative+false-positive), positive
predictive value (PPV, true-positive / true-positive
+   false-positive),   negative   predictive   value   (NPV,
true-negative/true-negative+false-negative), positive
likelihood ratio (LR+, sensitivity/1-specificity), and the
negative likelihood ratio (LR-, 1-sensitivity / specificity)
were calculated.
Results
We have assessed the effects of urine properties on the
Berry spot test. There was not any significant difference
between urine characteristics with test results (Data
not shown). For evaluation of those parameters that
could result in erroneous outcomes in the DMB test,
we distributed all samples into three groups based on
the WBC cell counts in urine (Table 1). Total urinary
glycosaminoglycans decreased in urine samples with
a WBC cell count greater than 10 cells compared to
samples with lower than 4 cells (Table 1). A similar
alteration was also observed for urine epithelial cell
counts: GAGs concentration being highest in Group 1
(samples with cell counts lower than 4 cells) and the
lowest in Group 3 (samples with cell counts higher than
10 cells). On the other hand, despite apparent reductions
in the GAGs level by the decline of the urine WBC
and epithelial cell counts, a statistically significant
correlation was not detected between Groups 2 and the
other Groups (Table 1). Furthermore, we have evaluated
the effects of other urine parameters on measurement of
GAGs by the DMB colorimetric method. There was not
any significant difference between other parameters such
as urine pH, specific gravity (SG), and urine RBC with
GAGs concentration. Furthermore, despite trends to
decrease concentrations of urine GAGs with increasing
urine protein; there was no significant difference between
urine protein and GAGs (Data not shown).
In addition, we evaluated the change of GAGs
concentration in male and female subjects. Based on
the DMB method, there was a significant differences
between the urine GAGs in male and female subjects
(Figure 1). Male subjects showed significantly (p<0.05)
higher urine GAGs level than the female group did
(7.21± 3.68 and 4.4 ± 3.44 mg/g creatinine, respectively).
Furthermore, a One-Way ANOVA analysis followed by
Tukey tests confirmed that urine GAGs was remarkably
lower in Groups 4 and 5 of the age subclasses compared to
other Groups (Table 1), According to age classification.
The sensitivity and specificity of the Berry spot test was
83.33% and 88.88%, respectively. Table 2 shows the
other diagnostic utility for this test.
The means and standard deviations of urinary GAGs
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for MPSI and control groups were 12.54 ± 2.14 mg/g
creatinine and 4.67 ± 3.29 mg/g creatinine, respectively.
Using a cut-off level of 10.73 mg/g creatinine for
urinary GAGs, sensitivity, and specificity were 100%
and 97.22%, respectively. The area under the curve
for GAGs by Analysis of ROC curves (Figure 2) of
the DMB test was 0.99, 95% CI=0.973-1. The positive
predictive value (PPV), negative predictive value
(NPV), positive likelihood ratio, and negative likelihood
ratio of the tests were also determined. Table 2 shows
the abovementioned values for urine samples of the
studied subjects. The highest (97.22%) specificity and
highest (0.75) PPV could be obtained by quantitative
measurements of GAGs. Withinrun and betweenrun
CVs were obtained for the DMB test was 2% and 7%,
respectively.
discussion
In the present study, we assessed the diagnostic validity
of total glycosaminoglycans concentrations in the
urine of MPSI patients compared healthy subjects. The
random urine specimens were used for the DMB and
the Berry spot tests. There are many studies that use
random urine (8, 19) for measurement, but 24 h urine
samples have also been utilized (24). Mahalingam K
et al (25) used random urine for measurement of urine
GAGs in the concentration of GAGs in the control
group and MPS suspected patients were 2.5±2.09 and
12.64±12.83 mg, respectively. Additionally, de Jong JG
et al (26) also determined the urine GAGs in untimed
samples. The concentration of this marker in the patient
group ranged from 2.9±1.0 mg in 15–20 age years and
18.6±8.6 mg in 0–1 age years. On the other hand, Panin
G et al (27), which used 24 h urine samples, reported
that the concentration of GAGs in urine was 12.8±5.0
mg/24h for healthy subjects, but they concentrated
urine GAGs by cetylpyridinium chloride. There are
no reported discrepancies between the results of two
different sample collections; however, due to the age of
the MPSI patients it seems that random specimens are a
better choice for the assay.
We have evaluated the general properties of urine with
the DMB and the Berry spot test results. Urine pH, SG,
protein, WBC, epithelial cell, and bacteria count have
no significant reducing or increasing effect on the Berry 
spot test. The Berry spot test provides a rapid, simple,
and cheap qualitative evaluation of urine; however, the
low sensitivity and specificity have precluded its use
as a screening test (26, 28). Alternative spot tests also
dealt with the same disadvantages for false-negative and
false-positive specimens (18, 29, 30). De jong et al (23)
has shown that azure A dye based spot test (Ames spot
test) has a low reliability, with approximately 35% of
false-negative and 29% of false-positive results. The
Berry spot test sensitivity and specificity in our study
was 83.33% and 88.88%, respectively. The most logical
explanation for these results could be related to the
studied population. In our study, we assessed the MPSI
patients, whereas in other studies, all MPS patients were
assessed.
In this study, the mean concentration of urinary GAGs in
MPSI patients and control subjects was 12.54 ± 2.14 mg/g
creatinine and 4.67 ± 3.29 mg/g creatinine, respectively.
In a study that was carried out in Chile, the median
concentration of urinary GAGs/creatinine ratio in MPSI
patients was 2.83 (24). In another study in Taiwan, the
concentrations were 39.6 ± 11.8 mg/mmol creatinine for
the patients group (31). However, Gallegos-Arreola et
al (32) found that the highest levels of GAGs/creatinine
was in patients with Hurler syndrome (mean=627.7).
A comparison of these results revealed that there are
significant differences between GAGs concentrations
in different populations. This alteration could be due to
sampling and/or patient selection and analysis methods.
Although, due to lack of of patients in some age ranges,
an appropriate interpretation of age and urine GAGs
interactions could not be understood, our results revealed
that there is an indirect correlation between urinary
GAGs concentration and age; with increased age, the
mean concentration of GAGs decreased. These results
are supported by previous findings that revealed that
urine GAGs concentrations have a negative correlation
with age (6, 14, 24, 30, 32). A similar direct correlation
was also observed between urinary GAGs and urine
WBC and epithelial cell counts. Previous studies have
demonstrated some urine properties on colorimetric
assays of the GAGs. For example, many studies have
proved the interference of urine proteins on the DMB
assay (26, 33). We reported the negative effects of urine
WBC and epithelial cell counts on the DMB assay for the 
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G1 (<1year, n=40) G2 (1-2year, n=39) G3 (2-5year, n=37) G4 (5-9year, n=42) G5 (9-18year, n=42)
10.63 ± 2.92a 8.27 ± 2.15b 7.29 ± 3.29c 6.58 ± 4.36a,d 2.97 ± 2.24a,b,c,d
Urine WBC (Cell/HPF)
Less than 4 (n=113) 4-10 (n=42) More than 10 (n=45)
4.98 ± 3.79a 4.58 ± 1.97 1.99 ± 1.56a
Urine Epithelial (Cell/HPF)
Less than 4 (n=106) 4-10 (n=48) More than 10 (n=46)
5.24 ± 3.83a 3.03 ± 1.84 1.98 ± 2.05a
Data represented as Mean±SD.  
Data with similar letters (a, b, c or d) in each row represents significant difference (p<0.05)
Table 2.  Diagnostic value for Urine GAGs (DMB and Berry spot test)
Cut-off point lR+ lR- PPV nPV
Spot test Production of purple dye on paper 7.49 0.19 0.36 0.99
dMb test 10.73 (mg/g creatinine) 33.33 0.0 0.78 1.00
LR = Likelihood ratio; PPV = Positive predictive value; NPV = Negative predictive value; DMB = 1,9 Dimethylene Blue.
first time. Quantitative DMB methods make allowances
for variations in urine concentrations by reference to
specific gravity or creatinine concentrations. It is also
recommended that specimens should not be from an
early morning collection, have creatinine concentrations
less than 1.5 mmol/L, SG lower than 1.008, and should
not be infected (8, 17). In addition, our results clearly
show that the concentration of urine GAGs in male
subjects is higher than for females.
We showed high sensitivity and specificity of urinary
GAGs test based on DMB colorimetric assays. This
finding is similar to that reported by previous studies.
However, in this study we demonstrate that high
sensitivity and specificity of the GAGs assay in MPSI
patients. In the present study, the sensitivity and
specificity of the test was 100% and 97.22% for the
DMB assay, respectively. Sensitivity and specificity
reported by Mabe et al for the DMB test was 100% and
74.5%, respectively (24). It is the highest value that is
reported for this test. Previous studies have shown that
Validation of Urinary gAgs According to Urine Characteristics
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time-consuming tests, such as enzyme and molecular
genetic assays.
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the sensitivity and specificity for the DMB test ranged
from 96–100% and 94–100%, respectively (31, 33, 34).
These findings show that the overall specificity of test is
high and  that this test has a low number of false-positive
results,  and  could     mitigate  the  disease  in  healthy
subjects. In addition, because of the high sensitivity of
the test, it rarely misses true positives among those who
are actually positive.
In   summary,  we  have   shown  the   high  sensitivity
and specificity of the DMB test for determination of
urine  GAGs.  In  addition,  our  results  also  show  an
opposite correlation between the ages of patients with
concentrations of urinary GAGs. Nevertheless, the
results of the present study reveal that, some urine
characteristics such as urine WBC and epithelial cell
count might result in false-negative results.
It can be concluded that the determination of urinary
GAGs might be a simple, rapid, and inexpensive
diagnostic tool for screening and monitoring of
MPSI patients before using costly, laborious, and
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first time. Quantitative DMB methods make allowances 
for variations in urine concentrations by reference to 
specific gravity or creatinine concentrations. It is also 
recommended that specimens should not be from an 
early morning collection, have creatinine concentrations 
less than 1.5 mmol/L, SG lower than 1.008, and should 
not be infected (8, 17). In addition, our results clearly 
show that the concentration of urine GAGs in male 
subjects is higher than for females.
We showed high sensitivity and specificity of urinary 
GAGs test based on DMB colorimetric assays. This 
finding is similar to that reported by previous studies. 
However, in this study we demonstrate that high 
sensitivity and specificity of the GAGs assay in MPSI 
patients. In the present study, the sensitivity and 
specificity of the test was 100% and 97.22% for the 
DMB assay, respectively. Sensitivity and specificity 
reported by Mabe et al for the DMB test was 100% and 
74.5%, respectively (24). It is the highest value that is 
reported for this test. Previous studies have shown that 
the sensitivity and specificity for the DMB test ranged 
from 96–100% and 94–100%, respectiv ly (31, 33, 34). 
These findings show that the overall specificity of test is 
high and  that this test has a low number of fals -positive 
results, and could  mitigate the disease in healthy 
subjects. In addition, because of th  high s nsitivity of 
the test, it rarely misses true positives among those who 
are actually positive. 
In summary, we have shown the high sensitivity 
and specificity of the DMB test for determination of 
urine GAGs. In addition, our results also show an 
opposite correlation between the ages of patients with 
concentrations of urinary GAGs. Nevertheless, the 
results of the present study reveal that, some urine 
characteristics such as urine WBC and epithelial cell 
count might result in false-negative results. 
It can be concluded that the determination of urinary 
GAGs might be a simple, rapid, and inexpensive 
diagnostic tool for screening and monitoring of 
MPSI patients before using costly, laborious, and 
time-consuming tests, such as enzyme and molecular 
genetic assays.
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